JP2023511774A5 - - Google Patents
Info
- Publication number
- JP2023511774A5 JP2023511774A5 JP2022546621A JP2022546621A JP2023511774A5 JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5 JP 2022546621 A JP2022546621 A JP 2022546621A JP 2022546621 A JP2022546621 A JP 2022546621A JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- represented
- antibody
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026004811A JP2026086434A (ja) | 2020-01-31 | 2026-01-15 | 抗トランスフェリン受容体(tfr)抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968252P | 2020-01-31 | 2020-01-31 | |
| US62/968,252 | 2020-01-31 | ||
| US202063055405P | 2020-07-23 | 2020-07-23 | |
| US63/055,405 | 2020-07-23 | ||
| PCT/US2021/012666 WO2021154476A1 (en) | 2020-01-31 | 2021-01-08 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026004811A Division JP2026086434A (ja) | 2020-01-31 | 2026-01-15 | 抗トランスフェリン受容体(tfr)抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511774A JP2023511774A (ja) | 2023-03-22 |
| JP2023511774A5 true JP2023511774A5 (cg-RX-API-DMAC7.html) | 2024-01-18 |
| JP7807379B2 JP7807379B2 (ja) | 2026-01-27 |
Family
ID=77079923
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546621A Active JP7807379B2 (ja) | 2020-01-31 | 2021-01-08 | 抗トランスフェリン受容体(tfr)抗体およびその使用 |
| JP2026004811A Pending JP2026086434A (ja) | 2020-01-31 | 2026-01-15 | 抗トランスフェリン受容体(tfr)抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026004811A Pending JP2026086434A (ja) | 2020-01-31 | 2026-01-15 | 抗トランスフェリン受容体(tfr)抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230113823A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4096695A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7807379B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220134584A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427059A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213042A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014771A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163290A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295022A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009418A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154476A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP4087653A4 (en) * | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| IL318627A (en) * | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| WO2024168801A1 (zh) * | 2023-02-17 | 2024-08-22 | 南京融捷康生物科技有限公司 | 抗TfR1的单域抗体及其用途 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| WO2025265092A1 (en) * | 2024-06-21 | 2025-12-26 | Dyne Therapeutics, Inc. | Complexes and uses thereof for treating pompe disease |
| CN120209138B (zh) * | 2025-05-29 | 2025-10-03 | 杭州广科安德生物科技有限公司 | Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| CA2922544A1 (en) * | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| IL257065B (en) * | 2015-07-22 | 2022-07-01 | Inatherys | Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases |
| AU2016335750B2 (en) * | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
| KR20250007678A (ko) * | 2016-05-13 | 2025-01-14 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| TWI833178B (zh) * | 2016-12-26 | 2024-02-21 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| CN118638787A (zh) * | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| CN111683972A (zh) * | 2018-02-05 | 2020-09-18 | Jcr制药股份有限公司 | 用于将药剂递送至肌肉的方法 |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
-
2021
- 2021-01-08 IL IL295022A patent/IL295022A/en unknown
- 2021-01-08 US US17/796,418 patent/US20230113823A1/en active Pending
- 2021-01-08 BR BR112022014771A patent/BR112022014771A2/pt unknown
- 2021-01-08 EP EP21748405.4A patent/EP4096695A4/en active Pending
- 2021-01-08 JP JP2022546621A patent/JP7807379B2/ja active Active
- 2021-01-08 CN CN202180025161.4A patent/CN115427059A/zh active Pending
- 2021-01-08 KR KR1020227029398A patent/KR20220134584A/ko active Pending
- 2021-01-08 MX MX2022009418A patent/MX2022009418A/es unknown
- 2021-01-08 CA CA3163290A patent/CA3163290A1/en active Pending
- 2021-01-08 AU AU2021213042A patent/AU2021213042A1/en active Pending
- 2021-01-08 WO PCT/US2021/012666 patent/WO2021154476A1/en not_active Ceased
-
2026
- 2026-01-15 JP JP2026004811A patent/JP2026086434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| US9758586B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
| JP7663977B2 (ja) | 抗pd―l1抗体およびその用途 | |
| WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
| AU2010238723A1 (en) | Anti-human ROR1 antibodies | |
| KR20140034877A (ko) | 항슈도모나스 psl 결합 분자 및 그의 용도 | |
| CN110856446A (zh) | 抗pd-l1抗体及其用途 | |
| KR20130130825A (ko) | 골관절염 및 통증의 치료 방법 | |
| TW201026325A (en) | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| WO2021155635A1 (zh) | 抗cd3和cd123双特异性抗体及其用途 | |
| KR20230125042A (ko) | 항-tslp 나노항체 및 이의 응용 | |
| JP7755062B2 (ja) | 新規抗l1cam抗体 | |
| TW202506189A (zh) | 配體-細胞毒性藥物綴合物及其醫藥用途 | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| US20240075158A1 (en) | Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof | |
| JP2025506248A5 (cg-RX-API-DMAC7.html) | ||
| TW202535883A (zh) | 配體–細胞毒性藥物偶聯物及其藥物用途 | |
| JP2025524306A (ja) | Itga2を標的とする抗体及びそれを含む抗体薬物複合体 | |
| IL324637A (en) | Antibody specifically binding to cll1, and preparation method therefor and use thereof | |
| CN120424212A (zh) | 抗FGFR2b抗体及抗体药物偶联物 | |
| TW202432185A (zh) | 配體-細胞毒性藥物綴合物及其藥物用途 | |
| CN120187752A (zh) | 人源化的l1cam抗体药物偶联物 | |
| TWI843182B (zh) | 一種抗b7-h4抗體及其製備方法和應用 | |
| TW202434637A (zh) | 抗體、抗原結合片段及其醫藥用途 |